PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “NEOPLASMS, EXPERIMENTAL”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1977

[Immunologic reactivity of the body after laser irradiation of experimental neoplasms].

The irradiation of Garding-Passey and B16 melanomas results in an increased number of antibody-forming cells (AFC) in the spleen and an increased level in blood serum of autoantibodies against antigens of the irradiated tumor and of the liver and kidneys of the same animals, as well. Some increase of these indices was noted also in the irradiation of normal tissues.

Animals↗
PubMed1984

The effects of tubulazole, a new synthetic microtubule inhibitor on experimental neoplasms.

Tubulazole, a new synthetic microtubule inhibitor in vitro, is tested in vivo upon three experimental neoplasms: MO4 sarcoma, L1210 leukemia and TA3 carcinoma. The compound is tested using different treatment schedules upon different inoculation routes of the cells. All trials show the compound to have distinct antineoplastic properties in vivo by prolonging the median survival time. The best treatment schedule seems to be an intermittent one, i.e. treatment every fourth day starting 1 day after tumor inoculation. Comparison with cyclophosphamide and vincristine is in favor of tubulazole for treating TA3 mammacarcinoma, while cyclophosphamide and vincristine give somewhat better results upon L1210 leukemia. The effects of tubulazole and cyclophosphamide upon MO4 fibrosarcoma are comparable, while vincristine has no effect in this system. Worthwhile noting is that all the in vivo, as well as in vitro, activity of tubulazole resides in the cis isomer, while the trans isomer has no effect at all.

Animals↗